# Clinical Trials Data EGFR - Document 16

# The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib

## Clinical Trial: https://clinicaltrials.gov/study/NCT01608841

"eligibilityCriteria": "Inclusion Criteria:\n\n\* metastatic chemotherapy-na\u00efve pancreatic cancer patients\n\* histologically confirmed\n\* adequate samples for analysis\n\* Eastern Cooperative Oncology Group (ECOG) performance status \\<= 2\n\* absolute neutrophil count (ANC) \\>= 1,500/mm3\n\* platelet count \\>= 100,000/mm3\n\* serum creatinine \\<= 1.5 mg/dL\n\* aspartate aminotransferase (AST)\n\* alanine aminotransferase (ALT) \\< 5 times the upper limit of normal\n\nExclusion Criteria:\n\n\* absence of any other malignancy or serious medical or psychological illness that would preclude informed consent",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
]

Question:  
Based on the following clinical trial information, would a patient with a EGFR gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided eligibility criteria for the clinical trial, there is no specific mention of exclusions related to the presence of an EGFR gene mutation. The inclusion and exclusion criteria primarily focus on the type and stage of cancer (metastatic chemotherapy-naïve pancreatic cancer), performance status, blood counts, liver and kidney function, and the absence of other malignancies or serious medical conditions.   
  
Therefore, having an EGFR gene mutation is not listed as an exclusion criterion. As long as the patient meets all other listed criteria, such as having metastatic chemotherapy-naïve pancreatic cancer, adequate performance status (ECOG ≤ 2), and the specified lab values, they would likely be eligible for the trial regardless of their EGFR mutation status. However, it's always important to confirm specifics with the trial investigators or coordinators, as there may be additional unstated conditions or considerations.